This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug development.

该统一平台将序列设计、化学修饰、实验验证、肝外递送设计以及知识产权策略整合到一个计算与实验相结合的工作流程中，并开创性地建立体内疗效预测模型，以加速药物研发进程。

Validating this infrastructure, XtalPi announced the advancement of six proprietary preclinical programs targeting complex diseas

在验证这一基础设施的同时，晶泰科学宣布推进六个针对复杂疾病的专有临床前项目。

es, with

是的，与

the first one reaching NHP data in just 7 months; in utilizing optimized ligand-based delivery mechanisms, XtalPi is advancing RNA interference therapies beyond the liver.

首个在短短7个月内就获得非人灵长类动物数据的项目；通过利用优化的配体递送机制，晶泰智能正在推动RNA干扰疗法超越肝脏局限。

Internal preclinical data benchmarking demonstrates a nearly threefold increase in molecular design efficiency compared to conventional workflows, alongside a first-round in vivo hit rate exceeding 50% across multiple target programs.

内部临床前数据基准测试表明，与传统工作流程相比，分子设计效率提高了近三倍，同时在多个靶点项目中，首轮体内命中率超过50%。

BOSTON and BEIJING

波士顿和北京

,

，

Oct. 6, 2026

2026年10月6日

/PRNewswire/ -- XtalPi Holdings

/美通社/ -- 晶泰科技控股有限公司

Limited

有限

(HKEX: 2228), an AI and robotics-driven drug and materials discovery company, today debuted Kodexia™, the industry's first closed-loop small interfering RNA (siRNA) discovery platform combining generative AI, first-principles-driven biological modeling, and automated experimentation. Validating the rapid execution capabilities of this new infrastructure, the company simultaneously announced the advancement of six proprietary therapeutic programs, marking the successful expansion of XtalPi's technology into nucleic acid therapeutics..

（港交所：2228），一家由人工智能和机器人驱动的药物与材料发现公司，今日正式推出Kodexia™，这是业界首个将生成式人工智能、基于第一性原理的生物建模以及自动化实验相结合的闭环小干扰RNA（siRNA）发现平台。为验证这一新基础设施的快速执行能力，该公司同时宣布推进六个自有治疗项目，标志着晶泰科技（XtalPi）的技术成功拓展至核酸治疗领域。

By silencing disease-driving genes upstream of protein production, siRNA therapeutics offer immense potential for biological targets that conventional modalities struggle to address. However, clinical development remains heavily constrained by fragmented sequence and modification design processes, restrictive patent barriers, inconsistent translation from cellular assays to animal models, and severe limitations in extrahepatic delivery..

通过在蛋白质产生之前沉默致病基因，siRNA疗法为传统方法难以应对的生物靶点提供了巨大的潜力。然而，其临床开发仍受到严重制约，主要瓶颈包括：序列与修饰设计流程的碎片化、严格的专利壁垒、从细胞实验到动物模型的转化结果不一致，以及肝外递送方面的严重局限性。

To address these interdependent bottlenecks, XtalPi drew on domain-specific expertise to develop siFormer, the proprietary architecture at the core of Kodexia™. By seamlessly integrating RNAi biological mechanisms with nucleic acid chemistry principles,

为应对这些相互依赖的瓶颈，晶泰科技凭借领域专业知识开发了 siFormer，这是 Kodexia™ 的核心专有架构。通过将 RNAi 生物机制与核酸化学原理无缝整合，

siFormer

siFormer

delivers a qualitative leap in predictive accuracy that surpasses conventional design baselines. The architecture incorporates RNA thermodynamics and structural features relevant to strand loading, target accessibility, and silencing efficiency. These mechanistic constraints guide molecular generation toward biologically plausible designs rather than relying on sequence correlations alone.

实现了预测准确性的质的飞跃，超越了传统的设计基准。该架构整合了与链加载、靶标可及性和沉默效率相关的RNA热力学和结构特征。这些机制约束引导分子生成朝向生物学上合理的设计，而非仅仅依赖序列相关性。

Through this unified approach, Kodexia™ enables researchers to systematically balance potency, in vivo translation, durability, off-target activity, safety, and patentability instead of optimizing single endpoints in isolation..

通过这一统一方法，Kodexia™ 使研究人员能够系统地平衡效力、体内转化性、持久性、脱靶活性、安全性和可专利性，而非孤立地优化单一终点指标。

To execute this multiparameter optimization, XtalPi utilizes a closed-loop process of computational design, automated experimentation, and empirical feedback. Generative models and the proprietary siFormer architecture operate continuously with XtalPi's automated laboratories, which conduct more than 500 in vitro and 30 in vivo experiments weekly.

为执行这一多参数优化，XtalPi 采用了一个包含计算设计、自动化实验和经验反馈的闭环流程。生成式模型和专有的 siFormer 架构与 XtalPi 的自动化实验室持续协同运行，这些实验室每周进行超过 500 次体外实验和 30 次体内实验。

This seamless integration enables the parallel development of multiple target programs, yielding a nearly threefold increase in design efficiency. Notably, more than 50% of first-round designs tested across multiple programs showed stronger in vivo activity than positive controls..

这种无缝集成实现了多个目标程序的并行开发，使设计效率提高了近三倍。值得注意的是，在多个程序中测试的首轮设计中，超过50%显示出比阳性对照更强的体内活性。

Kodexia™ also globally co-optimizes dual-target siRNAs as single molecules, creating a strategy for disease biology that may not be adequately addressed through single-target intervention. For extrahepatic delivery, the platform co-designs siRNA molecules with their targeting systems and applies multi-objective optimization to antibody, peptide, and small-molecule conjugates.

Kodexia™ 还在全球范围内将双靶点 siRNA 作为单分子进行协同优化，从而为疾病生物学提供一种通过单靶点干预可能无法充分解决的策略。针对肝外递送，该平台将 siRNA 分子与其靶向系统共同设计，并对抗体、肽和小分子偶联物应用多目标优化。

These capabilities are being applied to delivery research targeting the kidney, spleen, and adipose tissue..

这些能力正被应用于针对肾脏、脾脏和脂肪组织的递送研究。

The platform's lead program in immunoglobulin A (IgA) nephropathy serves as an early empirical validation of this unified architecture. The program reached non-human primate efficacy data within seven months, demonstrating greater activity and durability than a clinical-stage reference molecule targeting the same target.

该平台在免疫球蛋白A（IgA）肾病方面的领先项目，为这一统一架构提供了早期的实证验证。该项目在七个月内获得了非人灵长类动物的疗效数据，显示出比针对同一靶点的临床阶段参考分子更强的活性和更持久的效果。

The program is on track for preclinical candidate selection within a nine-month project timeline, significantly accelerating the industry norm of 12 to 18 months..

该项目正按计划推进，预计在九个月的项目周期内完成临床前候选药物的筛选，显著快于行业通常所需的12至18个月。

Kodexia™ currently drives six proprietary programs across metabolic, renal, respiratory, and central nervous system diseases, with more than half having already completed in vivo efficacy evaluations. Each internal program generates high-value experimental data that feeds directly back into the platform's models, reinforcing a continuous cycle of discovery and commercial translation.

Kodexia™ 目前在代谢、肾脏、呼吸和中枢神经系统疾病领域推进六个专有项目，其中超过一半已完成体内药效评估。每个内部项目均产生高价值的实验数据，并直接反馈至平台模型中，从而强化发现与商业化转化的持续循环。

As a global scientific utility platform, XtalPi leverages this capability alongside its established expertise in small molecules, antibodies, and peptides. By advancing these internal assets in tandem with established industry collaborations, XtalPi empowers its partners to pursue high-value targets using the modality best suited to the mechanistic and biophysical principles of RNA interference, including RNA thermodynamics and structural features, ultimately accelerating the delivery of next-generation RNA therapies for patients worldwide..

作为全球科学实用平台，XtalPi 将这一能力与其在小分子、抗体和肽类领域的既有专业知识相结合。通过将这些内部资产与成熟的行业协作同步推进，XtalPi 赋能合作伙伴采用最契合 RNA 干扰机制及生物物理原理（包括 RNA 热力学和结构特征）的模态来攻克高价值靶点，从而加速向全球患者提供下一代 RNA 疗法。

About XtalPi

关于晶泰科学

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries..

晶泰科学控股有限公司（XtalPi，股票代码：2228.HK）由三位来自麻省理工学院（MIT）的物理学家于2015年创立。它是一个以量子物理、人工智能和机器人技术为驱动的创新研发平台。通过整合第一性原理计算、人工智能算法、高性能云计算以及标准化自动化系统，晶泰科学为制药、材料科学、农业科技、能源、新型化学品及化妆品行业的企业提供数字化与智能化的研发解决方案。

SOURCE XtalPi Inc.

来源：晶泰科学

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示